10/533833

JC06 Rec'd PCT/PTO 03 MAY 2005
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

Based on PCT/JP2003/014101

Filed:

Intl. Filing 05 NOVEMBER 2003

1st Inventor:

Masahiro KAJINO

For:

Receptor Regulator

Atty. Dkt. No.

3116 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted

(847) 383-3372 (847) 383-3391 Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

10/533833

JC06 Rec'd PCT/PTO 03 MAY 2005

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	estitute for form 1449/PTO	Complete if Known		
		Application Number	Based on PCT/JP03/14101	
18	FORMATION DISCLOSURE	Filing Date	Intl. Filing 05 NOV 2003	
		First Named Inventor	Masahiro KAJINO	
S	TATEMENT BY APPLICANT	Art Unit	tba	
(Use as many sheets as necessary)		Examiner Name	tba	
Sheet	1 of 2	Attorney Docket Number	3116 US0P	

Examiner	Cite	Document Number	Publication Date	IT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where	
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	A1	^{US-} 4,126,689	11/21/1978	Stefan Sanczuk, et al.	
	A2	^{US-} 4,791,120	12/13/1988	Bor-Sheng Lin, et al	
		US-			
		US-	***************************************		
		US-	_		
		US-			
-		US-			
		US-	•		
-		US-			
****		US-			
		US-			
		US-		+	

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
*****		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ'
	A3	WO 01/44297 A1	06/21/2001	Synaptic Pharmaceutical		
	A4	EP 1255109 A1	11/06/2002	Takeda Chemical Industries		
	A5	WO 00/02919	01/20/2000	Merck & Co., Inc.		
	A6	EP 1237001 A1	09/04/2002	Takeda Chemical Industries		Г
	A7	JP 01-213279 - Abstract	08/28/1989	BOC Group, Inc.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/533833

JC06 Rec*d PCT/PTO 03 MAY 2005

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO		e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitute to form 1443/FTO				Application Number	Based on PCT/JP03/14101
INFORMATION DISCLOSURE				Filing Date	Intl. Filing 05 NOV 2003
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Masahiro KAJINO
	(Use as many sheets as necessary)			Art Unit	tba
(ose as many sneets as necessary)			ecessary)	Examiner Name	tba
Sheet	2	of	2	Attorney Docket Number	3116 US0P

6)

- O:t	NON PATENT LITERATURE DOCUMENTS	
No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A8	L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32.	
А9	N. SAKURA, et al., "StructureActivity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, Vol. 48, No. 8.	
A10	M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acting Opiod Agonist, Remifentanil", Synlett, (1999), pp. 1923-1224, No. 12.	
A11	N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3.	
A12	L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7.	
A13	D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155.	
A14	S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41.	
A15	C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52.	
A16	K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1997), pp. 426-434, Vol. 46.	
	A8 A9 A10 A11 A12 A13 A14	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32. N. SAKURA, et al., "StructureActivity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, Vol. 48, No. 8. M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acting Opiod Agonist, Remifentanil", Synlett, (1999), pp. 1923-1224, No. 12. N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3. L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7. D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155. S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41. C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52. K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors",

				_
Examiner	-	Date	-	
Signature		Considered		ļ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.